CALGARY,
AB, April 6, 2022 /CNW/ - Universal
Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or
the "Company") a life sciences company with a mission to
transform the world of addiction treatment through medicalized
ibogaine and a state of the art ongoing care program, is pleased to
announce that its common shares have been approved for trading on
the Frankfurt Stock Exchange, or Bourse Frankfurt (the
"FSE") under the ticker symbol "JC4". UI will
continue to trade in Canada on the
TSX Venture Exchange under its current ticker symbol IBO and on the
OTCQB under the ticker symbol IBOGF.
The FSE is the largest stock exchange in Germany and is the premiere European
destination for Canadian Venture companies looking to build
exposure and liquidity with the European market. The FSE
facilitates advanced electronic trading, settlement and information
systems allowing it to meet the growing requirements of
cross-border trading.
Global Addiction and the Overdose
Crisis
According to an August 4, 2021,
World Health Organization report, worldwide approximately 500,000
deaths annually can be attributed to drug use, with more than 70%
related to opioids.
"The number of opioid overdoses has increased in recent years
in several countries, in part due to the increased use of opioids
in the management of chronic pain and increasing use of highly
potent opioids appearing on the illicit drug market.
In the United States of
America (USA) the number of
people dying from opioid overdose increased by 120% between 2010
and 2018, and two-thirds of opioid-related overdose deaths in 2018
in the USA involved synthetic
opioids, including fentanyl and its analogues.
During the COVID-19 pandemic, a further substantial
increase in drug overdose deaths was reported in the USA, primarily driven by rapid increases in
overdose deaths involving synthetic opioids."
https://www.who.int/news-room/fact-sheets/detail/opioid-overdose
What is ibogaine?
Ibogaine is a plant derived neuroactive compound that appears to
reset the brains of drug dependent individuals to a pre-addicted
state and has demonstrated particular effectiveness in treating
opioid use disorder in many countries. When applied according
to a strict safety protocol, including a medically supervised
setting, ibogaine appears to eliminate the most painful symptoms of
opioid withdrawal and can provide a several month window free of
drug cravings. Dr. Alberto
Sola, co-founder and member of the Board of Directors of
Universal Ibogaine, has administered more ibogaine treatments than
any other doctor in the world at an independent clinic (of which he
is a partner) in Cancun,
Mexico.
The Universal Ibogaine
Mission
Universal Ibogaine is a Canadian company which holds the global
licensing rights to the ibogaine based addiction treatment protocol
developed by Dr. Alberto Sola.
UI is working with Health Canada to undertake a planned clinical
trial in Canada to demonstrate the
safety and efficacy of the ibogaine treatment protocol for opioid
use disorder(s). Upon eventual completion of the trial and
Health Canada approval, UI intends to license the protocol to a
global network of addiction treatment clinics. Ibogaine can
be very effective for long term addiction cessation when combined
with an aftercare treatment program. Universal Ibogaine
operates an addiction treatment facility in Winnipeg, where it is intends to develop best
in class addiction treatment programs built around evidence based
treatments and nuovo modalities.
Universal Ibogaine CEO Nick
Karos commented "the FSE listing is a key piece of
our capital markets and investor relations strategy. We have
recently commenced trading on the OTCQB Exchange in the
USA, and interest in the UI story
is growing in Europe and
Germany in particular.
Germany has a history of
innovation and leadership with an emerging market and interest in
psychedelic medicines."
About Universal Ibogaine
Inc.
UI is a life sciences company, with a mission to demonstrate the
safety and efficacy of its ibogaine based drug detox protocol
through a planned Canadian Clinical Trial, and ultimately to
utilize that protocol around the globe through future licensing
agreements. UI is concurrently developing a state of the art
holistic addiction treatment protocol at its Kelburn Clinic that,
which when paired with the planned ibogaine detox protocol, is
intended to revolutionize the way we treat addiction and
drastically improve the lives of individuals and families affected
by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and
information. Forward-looking information is frequently
characterized by words such as "plans", "expect", "project",
"intend", "will", "believe", "anticipate", "estimate", "scheduled",
"potential", or other similar words, or statements that certain
events or conditions "may", "should" or "could" occur. The
forward-looking statements and information are based on certain key
expectations and assumptions made by UI. Although UI
believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements
because UI can give no assurance that they will prove to be
correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to a number of factors and risks, which
include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that
assumptions used in the preparation of such information, although
considered reasonable by UI at the time of preparation, may prove
to be incorrect and readers are cautioned not to place undue
reliance on forward-looking information, which speaks only to
conditions as of the date hereof. UI does not undertake any
obligation to release publicly any revisions to forward-looking
information contained herein to reflect events or circumstances
that occur after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable
securities laws.
Related
Links
https://universalibogaine.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/universal-ibogaine-announces-frankfurt-stock-exchange-listing-301518668.html
SOURCE Universal Ibogaine Inc.